tiprankstipranks
Natural Beauty Bio-Technology Limited (HK:0157)
:0157

Natural Beauty Bio-Technology (0157) AI Stock Analysis

Compare
0 Followers

Top Page

HK:0157

Natural Beauty Bio-Technology

(0157)

Select Model
Select Model
Select Model
Neutral 48 (OpenAI - 5.2)
Rating:48Neutral
Price Target:
HK$0.48
▼(-3.06% Downside)
Action:ReiteratedDate:03/12/26
The score is primarily held back by persistent negative operating/free cash flow despite the 2025 earnings rebound, alongside a high P/E valuation. Technical indicators are only mildly supportive, with mixed momentum and a generally weak longer-term trend versus key moving averages.
Positive Factors
Branded consumables model
Natural Beauty's core business is branded skincare and cosmetics sold through multi-channel distribution and consultant networks. That consumable product model supports recurring purchases and customer retention, giving a durable revenue base less dependent on one-off sales or fleeting trends.
Negative Factors
Persistent negative cash flow
Despite accounting profits in 2025, the company continues to burn cash with negative operating and free cash flow, a multi-year pattern. Persistent cash deficits force reliance on external financing or asset sales, increase refinancing risk, and limit capacity to invest in marketing, R&D, or distributor incentives over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Branded consumables model
Natural Beauty's core business is branded skincare and cosmetics sold through multi-channel distribution and consultant networks. That consumable product model supports recurring purchases and customer retention, giving a durable revenue base less dependent on one-off sales or fleeting trends.
Read all positive factors

Natural Beauty Bio-Technology (0157) vs. iShares MSCI Hong Kong ETF (EWH)

Natural Beauty Bio-Technology Business Overview & Revenue Model

Company Description
Natural Beauty Bio-Technology Limited, an investment holding company, offers skin care products and services in in the People's Republic of China, Taiwan, and internationally. The company manufactures and sells skin care, beauty, aroma-therapeutic...
How the Company Makes Money
Natural Beauty Bio-Technology primarily makes money by selling branded beauty and skincare products. Revenue is generated from (1) product sales through its distribution network, including direct selling/beauty consultants and other sales channels...

Natural Beauty Bio-Technology Financial Statement Overview

Summary
Income statement rebounded in 2025 (revenue +16.78% YoY; profitability turned positive), and the balance sheet remains serviceable, but operating margins are still thin and results have been volatile. The biggest constraint is cash flow: operating cash flow and free cash flow were negative in 2025 and free cash flow has been negative in most recent years, raising sustainability and funding risk.
Income Statement
54
Neutral
Balance Sheet
66
Positive
Cash Flow
33
Negative
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue538.83M353.65M336.01M335.88M487.81M
Gross Profit269.54M202.33M200.34M165.33M281.80M
EBITDA56.48M-65.50M22.91M15.09M85.23M
Net Income10.58M-103.61M-15.11M-30.47M35.26M
Balance Sheet
Total Assets931.55M772.93M882.58M883.53M937.16M
Cash, Cash Equivalents and Short-Term Investments112.12M116.51M166.81M168.61M197.08M
Total Debt319.30M212.13M186.29M143.48M129.07M
Total Liabilities457.56M325.34M308.06M286.07M279.24M
Stockholders Equity473.98M447.59M574.52M597.46M657.92M
Cash Flow
Free Cash Flow-93.91M-54.96M-47.39M-35.98M4.67M
Operating Cash Flow-25.66M-13.75M21.72M8.33M42.78M
Investing Cash Flow-68.95M-40.17M-67.61M-38.77M-31.21M
Financing Cash Flow84.61M15.34M42.63M13.21M10.42M

Natural Beauty Bio-Technology Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.49
Price Trends
50DMA
0.49
Positive
100DMA
0.50
Positive
200DMA
0.52
Negative
Market Momentum
MACD
<0.01
Negative
RSI
57.80
Neutral
STOCH
76.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0157, the sentiment is Positive. The current price of 0.49 is below the 20-day moving average (MA) of 0.50, below the 50-day MA of 0.49, and below the 200-day MA of 0.52, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 57.80 is Neutral, neither overbought nor oversold. The STOCH value of 76.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0157.

Natural Beauty Bio-Technology Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
HK$486.05M5.2916.67%8.33%21.99%11.36%
64
Neutral
HK$403.12M10.473.39%15.24%-9.26%435.33%
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
62
Neutral
HK$615.65M6.414.03%-0.92%-71.88%
61
Neutral
HK$23.63B14.2039.14%2.53%20.78%18.37%
48
Neutral
HK$991.04M92.72-12.38%39.29%-71.82%
44
Neutral
HK$15.89B-12.50-6.34%5.00%2.79%-170.67%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:0157
Natural Beauty Bio-Technology
0.50
0.01
2.06%
HK:1925
Kwung's Holdings Limited
1.20
-0.09
-6.98%
HK:2145
Shanghai Chicmax Cosmetics Co., Ltd. Class H
59.35
14.13
31.25%
HK:2177
UNQ Holdings Limited
2.43
1.25
105.93%
HK:3332
Nanjing Sinolife United Co., Ltd. Class H
0.38
-0.12
-24.00%
HK:6993
Blue Moon Group Holdings Ltd.
2.71
-0.31
-10.26%

Natural Beauty Bio-Technology Corporate Events

Natural Beauty Bio-Technology Updates Audit Committee Charter to Meet HKEX Governance Standards
Mar 10, 2026
Natural Beauty Bio-Technology Limited has revised and adopted a new Audit Committee Charter, effective 10 March 2026, to align with updated corporate governance requirements of the Hong Kong Stock Exchange. The charter formalizes the committee&#82...
Natural Beauty Bio-Technology Publishes Audited 2025 Annual Results and Report
Mar 9, 2026
Natural Beauty Bio-Technology Limited has released its audited annual results for the year ended 31 December 2025, fulfilling Hong Kong listing requirements for preliminary annual results disclosure. The full 2025 annual report, including financia...
Natural Beauty Bio-Technology Sets March Board Meeting for 2025 Results
Feb 13, 2026
Natural Beauty Bio-Technology Limited has scheduled a board meeting for 9 March 2026 to review and approve its audited final results for the financial year ended 31 December 2025. The board will also consider recommending a final dividend, signali...
Natural Beauty Bio-Technology Flags Return to Profit on Surging Mainland China Sales
Feb 3, 2026
Natural Beauty Bio-Technology has issued a positive profit alert, indicating that its unaudited revenue for the year ended 31 December 2025 is expected to rise to approximately HK$530 million to HK$540 million, up about 50% to 53% from HK$353.6 mi...
Natural Beauty Bio-Technology Shareholders Unanimously Approve New Incentive Schemes
Dec 19, 2025
Natural Beauty Bio-Technology Limited announced that all resolutions put to shareholders at its extraordinary general meeting on 19 December 2025 in Taipei were approved by poll with 100% of votes cast in favour. The measures included adoption of ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Mar 12, 2026